Corvus Pharmaceuticals, Inc. (CRVS) Tops Q3 EPS by 47c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts CRVS Hot Sheet
Join SI Premium – FREE
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q3 EPS of $0.32, $0.47 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .
For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy shares fall despite beating Q3 estimates
- First Western Financial, Inc. (MYFW) Reports In-Line Q3 EPS
- Chemung Financial (CHMG) Tops Q3 EPS by 69c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
